Skip to main content

Table 2 Summary and distribution of fibrosis results according to group

From: HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa

  HBV/HIV HBV HIV Controls p
Valid Fibroscan 36/40 (90%) 38/41 (93%) 32/37 (86%) 29/30 (97%) 0.5
Fibroscan (kPa) n = 36 n = 38 n = 32 n = 29  
< 7.0 21 (58%) 19 (50%) 28 (88%) 23 (79%)  
7.0–13 11 (31%) 12 (32%) 1 (3%) 6 (21%) 0.002b
≥13 4 (11%) 7 (18%) 3 (9%)  
APRI n = 43 n = 35 n = 26 n = 22  
< 0.5 31 (72%) 25 (71%) 21 (81%) 19 (86%)  
0.5–1.5 9 (21%) 7 (20%) 4 (15%) 3 (14%) 0.8b
> 1.5 3 (7%) 3 (9%) 1 (4%)  
FIB-4 n = 42 n = 34 n = 26 n = 22  
< 1.30 31 (74%) 27 (79%) 19 (73%) 20 (91%)  
1.30–3.25 9 (21%) 4 (12%) 7 (27%) 2 (9%) 0.32b
> 3.25 2 (5%) 3 (9%)  
ALT, U/La 34 (24–45) 25 (22–47) 31 (21–44) 24 (19–39) 0.3
AST, U/La 31 (25–46) 27 (23–42) 32 (27–45) 21 (18–32) 0.001
Fibroscan, kPaa 6.2 (4.8–8.0) 6.9 (5.5–8.8) 4.7 (3.9–5.9) 5.6 (4.6–6.8) 0.001
APRIa 0.32 (0.24–0.58) 0.34 (0.21–0.66) 0.32 (0.23–0.46) 0.21 (0.13–0.42) 0.08
FIB-4a 0.96 (0.58–1.30) 0.86 (0.59–1.20) 0.77 (0.55–1.30) 0.63 (0.41–1.00) 0.1
  1. aMedian values and IQRs are shown in parenthesis
  2. bIndicates where a chi test was used
  3. The data in bold are entries where there were zero observations for the particular cell